Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb:74:101974.
doi: 10.1016/j.bpg.2025.101974. Epub 2025 Jan 11.

Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals

Affiliations
Free article
Review

Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals

Aleksander M Bogdanski et al. Best Pract Res Clin Gastroenterol. 2025 Feb.
Free article

Abstract

Pancreatic cancer is a highly lethal malignancy and is predicted to become the second leading cause of cancer-related deaths by 2030. Early detection significantly improves outcomes, but general population screening remains infeasible due to the low prevalence of the disease and lack of specific biomarkers. This review evaluates current recommendations for pancreatic cancer surveillance in high-risk individuals, synthesises evidence from recent studies and explores the sustainability of current imaging-based surveillance programmes. Challenges such as overdiagnosis, economic feasibility and disparities in access highlight the need for targeted, cost-effective strategies. Collaborative initiatives and consortia are needed to advance biomarker research and refine risk stratification. By integrating evidence-based recommendations with sustainable approaches, this review outlines pathways to improve early detection and reduce mortality from pancreatic cancer.

Keywords: Early detection; High-risk individuals; Pancreatic cancer; Screening; Surveillance.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Aleksander M. Bogdanski: none. Pilar Acedo: none. Michael B. Wallace: Consulting: Boston Scientific, ClearNote Health, Cosmo Pharmaceuticals, Endostart, Endiatix, Fujifilm, Medtronic, Surgical Automations, Ohelio Ltd, Venn Bioscience; Research grants: Fujifilm, Boston Scientific, Olympus, Medtronic, Ninepoint Medical, Cosmo/Aries Pharmaceuticals; Stock/Stock Options:, Virgo Inc., Surgical Automation; Consulting on behalf of Mayo Clinic: Boston Scientific. Microtek. Monique E. van Leerdam: none. Derk C.F. Klatte: none.

Similar articles

Substances

LinkOut - more resources